Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes

Pellegrino Musto, Antonietta Falcone, Grazia Sanpaolo, Carlo Bodenizza, Antonio La Sala, Gianni Perla, Angelo Michele Carella

Research output: Contribution to journalArticle

Abstract

Thirteen patients with low-to-intermediate risk myelodysplastic syndrome (MDS) received recombinant erythropoietin (r-EPO) at the single, weekly dose of 40.000 U for at least 8 weeks. Five patients (38.4%) achieved a major erythroid response (increased haemoglobin levels > 2 g/dl and/or transfusion independence), which is currently maintained after 3-11 months, without modification of r-EPO dose. This study suggests that 40.000 U r-EPO given once a week may be at least as effective as the more frequent (daily or three times a week) administrations of the drug usually employed in MDS patients.

Original languageEnglish
Pages (from-to)269-271
Number of pages3
JournalBritish Journal of Haematology
Volume122
Issue number2
DOIs
Publication statusPublished - Jul 2003

Keywords

  • Anaemia
  • Darboepoetin
  • Erythropoietin
  • Myelodysplastic syndromes
  • Transfusion

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes'. Together they form a unique fingerprint.

  • Cite this